Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
复制标题
DOI：
10.1016/j.addr.2011.12.005
复制
发表时间：
2012-05-15
影响因子：
16.1
通讯作者：
Banks, William A.
中科院分区：
文献类型：
--
作者：
Banks, William A.
关键词：
阿尔茨海默病(AD)的成功治疗将需要能够通过血脑屏障(BBB)的药物。然而，血脑屏障并不是一个简单的物理屏障，而是一个复杂的界面，与中枢神经系统(CNS)的其他部分密切联系，并受到周围组织的影响。本文从三个方面对AD患者的血脑屏障进行了研究。首先，它考虑了血脑屏障在AD的发生和发展中可能起到的作用。在这方面，血脑屏障本身就是治疗AD的靶点。其次，它研究了血脑屏障如何限制本来可能对治疗阿尔茨海默病有用的药物，并审查了正在开发的向中枢神经系统输送治疗阿尔茨海默病药物的策略。第三，它考虑了药物对AD血脑屏障的渗透与正常衰老的血脑屏障有何不同。在这种情况下，这些差异可能会使AD人群中抑郁症、精神错乱、精神病和疼痛控制等中枢神经系统疾病的治疗复杂化。
The successful treatment of Alzheimer’s disease (AD) will require drugs that can negotiate the blood-brain barrier (BBB). However, the BBB is not simply a physical barrier, but a complex interface that is in intimate communication with the rest of the central nervous system (CNS) and influenced by peripheral tissues. This review examines three aspects of the BBB in AD. First, it considers how the BBB may be contributing to the onset and progression of AD. In this regard, the BBB itself is a therapeutic target in the treatment of AD. Second, it examines how the BBB restricts drugs that might otherwise be useful in the treatment of AD and examines strategies being developed to deliver drugs to the CNS for the treatment of AD. Third, it considers how drug penetration across the AD BBB may differ from the BBB of normal aging. In this case, those differences can complicate the treatment of CNS diseases such as depression, delirium, psychoses, and pain control in the AD population.
登录
查看更多内容
影响因子：
3.7
作者：
Benedict, C;Hallschmid, M;Kern, W
通讯作者：
Kern, W
影响因子：
3.3
作者：
Banks, WA;Robinson, SM;Morley, JE
通讯作者：
Morley, JE
影响因子：
48
作者：
Barnes, Deborah E.;Yaffe, Kristine
通讯作者：
Yaffe, Kristine
影响因子：
4
作者：
Banks, William A.;Kumar, Vijaya B.;Morley, John E.
通讯作者：
Morley, John E.
影响因子：
82.9
作者：
Bard, F;Cannon, C;Yednock, T
通讯作者：
Yednock, T